GSK seeks EU approval for RSV vaccine for younger adults EU decision on expanded use expected by first half of 2026 June 13 (Reuters) - GSK (GSK.L), opens new tab has applied to the European ...

While GSK's vaccine was the first RSV vaccine to be approved by European and U.S. authorities in 2023 for older adults, it has since lagged behind rivals and sales have fallen sharply.

A decision by the European Union’s health regulator on the vaccine, already approved for certain age groups, is expected in the first half of 2026, GSK said.

GSK said a decision from the EU health regulator regarding this expanded use application is expected in the first half of 2026. Arexvy would be available to a broader adult population if the EMA ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of adults aged 18 to 59 years at increased risk for disease.

Expanded Approval: Moderna’s mRESVIA vaccine is now FDA-approved for adults aged 18–59 years with an increased risk for respiratory syncytial virus (RSV)-related lower respiratory tract disease.

Moderna’s RSV shot was the first non-COVID-19 mRNA vaccine to be approved in the United States. The Centers for Disease Control and Prevention’s (CDC) independent vaccine panel, the Advisory ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...

Nexstar Media Wire FDA approves expanded use of Moderna’s RSV shot, but uncertainty remains by: Nathaniel Weixel, The Hill Posted: Jun 13, 2025 / 02:41 PM CDT Updated: Jun 13, 2025 / 02:41 PM CDT ...

National FDA approves expanded use of Moderna’s RSV shot, but uncertainty remains by: Nathaniel Weixel, The Hill Posted: Jun 13, 2025 / 09:32 PM EDT Updated: Jun 13, 2025 / 09:32 PM EDT ...